文献速递耳科与耳神经

听力效用测量工具(HUM)在人工耳蜗候选者与使用者中的验证

Validation of the Hearing Utility Measure (HUM) in Cochlear Implant Candidates and Users.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-10-13

前瞻性队列研究纳入1315例人工耳蜗候选者,验证HUM与CIQOL-全球(r=0.69)及SSQ-总体(r=0.70)强相关,重测信度ICC为0.90。HUM在单侧聋候选者中为0.76,高于传统及非对称性听力损失者的0.58(P<.001)。结论认为HUM是可靠、有效且反应性良好的听力相关健康测量工具。

要点

  • HUM与CIQOL-全球(r=0.69)和SSQ-总体(r=0.70)强相关,支持结构效度。
  • HUM耳鸣域与THI呈负相关(-0.75),符合预期。
  • 重测信度ICC为0.90(95%CI 0.83-0.94),单侧聋候选者HUM为0.76,高于传统及非对称性听力损失者的0.58(P<.001)。

核心结论

  • HUM是成人重度听力损失中可靠、有效且反应性良好的听力相关健康测量工具。
  • HUM是基于偏好的效用工具,可用于成本效果评估,优于现有HUI-3,并补充现有非效用工具。

研究设计与样本

  • 前瞻性队列研究,在三级学术中心开展。
  • 2020年6月25日至2024年3月17日纳入人工耳蜗候选者,共1315例参与者。
  • 参与者在人工耳蜗评估时及激活后12个月完成HUM及其他评估,包括HUI-3、SSQ-49、CIQOL-35和THI。
  • 听力状态稳定的亚组间隔6个月完成两次HUM以评估重测信度。

主要发现

  • HUM与CIQOL-全球强相关(r=0.69;95%CI 0.66-0.72),与SSQ-总体强相关(r=0.70;95%CI 0.67-0.73)。
  • HUM耳鸣域与THI呈负相关(-0.75;95%CI -0.77至-0.73),符合预期。
  • 重测信度优秀(ICC 0.90;95%CI 0.83-0.94)。
  • 单侧聋候选者HUM听力效用为0.76,高于传统及非对称性听力损失者的0.58(P<.001)。
  • 单侧聋接受者HUM中位数从0.70改善至0.78(P=.002),传统接受者从0.57改善至0.75(P<.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate the Hearing Utility Measure (HUM), a tool designed to quantify hearing loss impact on health and quality of life for use in economic evaluation. STUDY DESIGN: Prospective cohort. SETTING: Tertiary academic center. METHODS: Cochlear implant (CI) candidates were enrolled between June 25, 2020, and March 17, 2024. Participants completed HUM alongside other assessments, including Health Utilities Index, Mark-3 (HUI-3), Speech, Spatial and Qualities of Hearing Scale (SSQ-49), Cochlear Implant Quality of Life Profile (CIQOL-35), and Tinnitus Handicap Inventory (THI) at the time of CI evaluation and 12 months post-activation. A subgroup with stable hearing status completed HUM twice, 6 months apart, to assess test-retest reliability. RESULTS: Among 1315 participants, HUM showed strong correlations with CIQOL-global (r = 0.69; 95% CI: 0.66-0.72) and SSQ-overall (r = 0.70; 95% CI: 0.67-0.73), supporting construct validity. HUM Tinnitus domain correlated negatively with THI (-0.75; -0.77, -0.73), as expected. Test-retest reliability was excellent (Intraclass Correlation Coefficient [ICC] 0.90, 95% CI: 0.83-0.94). HUM hearing utility was higher for candidates with single-sided deafness (SSD) (0.76) than with traditional and asymmetric hearing loss (0.58, P < .001). Median HUM improved from 0.70 to 0.78 for SSD recipients (P = .002) and 0.57 to 0.75 for traditional recipients (P < .001). CONCLUSION: HUM is a reliable, valid, and responsive measure of hearing-related health in adults with advanced hearing loss. Unlike traditional instruments such as SSQ and CIQOL, which capture patient-reported outcomes but are not designed for economic analysis, HUM is a preference-based utility instrument that enables cost-effectiveness evaluation. It outperforms the available HUI-3 by better reflecting hearing loss impact and complements existing nonutility instruments used in clinical and health policy decision-making.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Dixon PR, Shah AH, McRackan TR, et al. Validation of the Hearing Utility Measure (HUM) in Cochlear Implant Candidates and Users. Otolaryngol Head Neck Surg. 2025. PMID: 41084342. doi:10.1002/ohn.70033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。